A 2018 study from the Department of Pathology in the University of South Carolina School of Medicine, Columbia, published in Frontiers in Immunology, studied the treatment of EAE (encephalomyelitis: inflammation of the brain and spinal cord, typically due to acute viral infection) in mice with CBD oil in order to characterize the previously unknown biochemical mechanisms through which CBD inhibits MS-like symptoms.
*Note: Myeloid-derived suppressor cells, also known as immature myeloid cells, are another suspected factor in the onset of MS and MS-like symptoms – as they are known to suppress both innate and adaptive immunity.
With the given knowledge that EAE (encephalomyelitis: inflammation of the brain and spinal cord) in mice is triggered by Th1 and TH17 cells, researchers chose to examine the effect of CBD on the cytokines that affect these cells, as well as additional cytokines and other closely related transcription factors.
Taking into account both the differences in cytokine and transcription factors, the data indicates that CBD treatment leads to the suppression of cytokines and transcription factors that are known to display pro-inflammatory effects, while also promoting the production of IL10, a cytokine which is known to have strong anti-inflammatory properties.